Evidence map›Paper›PMID 24740411›Full record

ArticlePloS one2014

Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status.

Lena Pérez-Bercoff, Davide Valentini, Simani Gaseitsiwe, Shahnaz Mahdavifar, Mike Schutkowski, Thomas Poiret, Åsa Pérez-Bercoff, Per Ljungman, Markus J Maeurer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Immunoproteomics: The Evolution from Classical Methods to Emerging Techniques.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Lena Pérez-BercoffDepartment of Medicine Huddinge, Karolinska Institutet; Dept. of Hematology, Karolinska University Hospital, Stockholm, Sweden; CAST (Center for allogeneic stem cell transplantation), Karolinska Hospital.
Davide ValentiniCAST (Center for allogeneic stem cell transplantation), Karolinska Hospital.
Simani GaseitsiweMicrobiology, Tumor and Cell Biology (MTC), Stockholm, Sweden.
Shahnaz MahdavifarThe Swedish Institute for Infectious Disease Control (SMI), Stockholm, Sweden.
Mike SchutkowskiDepartment of Enzymology, Institute for Biochemistry and Biotechnology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Thomas PoiretDivision of Therapeutic Immunology (TIM), LabMed Karolinska Institutet, Stockholm, Sweden.
Åsa Pérez-BercoffDepartment of Genome Biology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
Per LjungmanDepartment of Medicine Huddinge, Karolinska Institutet; Dept. of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Markus J MaeurerCAST (Center for allogeneic stem cell transplantation), Karolinska Hospital; Division of Therapeutic Immunology (TIM), LabMed Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEAustralian National University · AUKarolinska University Hospital · SEMartin Luther University Halle-Wittenberg · DESwedish Institute · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytomegalovirus (CMV) infection represents a vital complication after Hematopoietic Stem Cell Transplantation (HSCT). We screened the entire CMV proteome to visualize the humoral target epitope-focus profile in serum after HSCT. IgG profiling from four patient groups (donor and/or recipient +/- for CMV) was performed at 6, 12 and 24 months after HSCT using microarray slides containing 17174 of 15mer-peptides overlapping by 4 aa covering 214 proteins from CMV. Data were analyzed using maSigPro, PAM and the 'exclusive recognition analysis (ERA)' to identify unique CMV epitope responses for each patient group. The 'exclusive recognition analysis' of serum epitope patterns segregated best 12 months after HSCT for the D+/R+ group (versus D-/R-). Epitopes were derived from UL123 (IE1), UL99 (pp28), UL32 (pp150), this changed at 24 months to 2 strongly recognized peptides provided from UL123 and UL100. Strongly (IgG) recognized CMV targets elicited also robust cytokine production in T-cells from patients after HSCT defined by intracellular cytokine staining (IL-2, TNF, IFN and IL-17). High-content peptide microarrays allow epitope profiling of entire viral proteomes; this approach can be useful to map relevant targets for diagnostics and therapy in patients with well defined clinical endpoints. Peptide microarray analysis visualizes the breadth of B-cell immune reconstitution after HSCT and provides a useful tool to gauge immune reconstitution.

Indexed as

Hematopoietic Stem Cell TransplantationB-LymphocytesCytokinesCytomegalovirusCytomegalovirus InfectionsEpitopesHumansImmunity, HumoralImmunoglobulin GProtein Array AnalysisProteomeViral ProteinsCytokinesEpitopesImmunoglobulin GProteomeViral Proteins

Identifiers

PMID24740411
PMCPMC3989190
OpenAlexW2055185517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.